Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations

Microbiology and Immunology

Volumn 51, Issue 11, 2007, Pages 1053-1059

  Maki, Katsuyuki ^a   Holmes, Ann R ^b   Watabe, Etsuko ^a   Iguchi, Yumi ^a   Matsumoto, Satoru ^a   Ikeda, Fumiaki ^a   Tawara, Shuichi ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antifungal; Candida albicans; Pharmacodynamics; Serum antifungal titer

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; POLYENE; PYRROLE DERIVATIVE;

ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SENSITIVITY; GROWTH INHIBITION; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCELIAL GROWTH; MYCOSIS; NONHUMAN;

CANDIDA ALBICANS;

EID: 36348993279     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb04000.x     Document Type: Article

References (21)

1. Abruzzo, G.K., Flattery, A.M., Gill, C.J., Kong, L., Smith, J.G., Krupa, D., Pikounis, V.B., Kropp, H., and Bartizal, K. 1995. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 39: 1077-1081.
2. Andes, D., and van Ogtrop, M. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43: 2116-2120.
3. Andes, D., Stamsted, T., and Conklin, R. 2001. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45: 922-926.
4. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47: 1179-1186.
5. Andes, D., Safdar, N., Marchillo, K., and Conklin, R. 2006. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50: 674-684.
6. Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., Denning, D.W., Donnelly, J.P., Edwards, J.E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, J.F., Patterson, T.F., Ritter, J., Selleslag, D., Shah, P.M., Stevens, D.A., and Walsh, T.J. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34: 7-14.
7. Aviles, P., Falcoz, C., San Roman, R., and Gargallo-Viola, D. 2000. Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis. Antimicrob. Agents Chemother. 44: 2333-2340.
8. Bekersky, I., Fielding, R.M., Dressler, D.E., Lee, J.W., Buell, D.N., and Walsh, T.J. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46: 834-840.
9. Denning, D.W. 2003. Echinocandin antifungal drugs. Lancet 362: 1142-1151.
10. Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Van Cutsem, J., and Cauwenbergh, G. 1989. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32 (Suppl 1): 67-87.
11. Hostetler, J.S., Heykants, J., Clemons, K.V., Woestenborghs, R., Hanson, L.H., and Stevens, D.A. 1993. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob. Agents Chemother. 37: 2224-2227.
12. Kauffman, C.A. 2006. Clinical efficacy of new antifungal agents. Curr. Opin. Microbiol. 9: 483-488.
13. Klepser, M.E., Wolfe, E.J., Jones, R.N., Nightingale, C.H., and Pfaller, M.A. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41: 1392-1395.
14. Louie, A., Drusano, G.L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., and Miller, M.H. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42: 1105-1109.
15. Maertens, J.A. 2004. History of the development of azole derivatives. Clin. Microbiol. Infect. 10 (Suppl 1): 1-10.
16. Maki, K., Watabe, E., Iguchi, Y., Nakamura, H., Tomishima, M., Ohki, H., Yamada, A., Matsumoto, S., Ikeda, F., Tawara, S., and Mutoh, S. 2006. Determination of antifungal activities in serum samples from mice treated with different antifungal drugs allows detection of an active metabolite of itraconazole. Microbiol. Immunol. 50: 281-292.
17. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pfaller, M.A., Sheehan, D.J., and Rex, J.H. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17: 268-280.
19. Pfaller, M.A., Diekema, D.J., and Sheehan, D.J. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19: 435-447.
20. Tkacz, J.S., and DiDomenico, B. 2001. Antifungals: what's in the pipeline. Curr. Opin. Microbiol. 4: 540-545.
21. Zhanel, G.G., Saunders, D.G., Hoban, D.J., and Karlowsky, J.A. 2001. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob. Agents Chemother. 45: 2018-2022.